

March, 2009

Columbus CCOP
1335 Dublin Road, Suite
124-A
Columbus, OH 43215

Phone: 614-488-2118
Fax: 614-488-2647
www.columbusccop.org

CCOP NEWS



A Community of Caring in Cancer Research

Columbus Community Clinical Oncology Program

CANCER CONTROL TRIALS ARE IMPORTANT!

The Columbus CCOP's goal, as established by the NCI, is to accrue 110 cancer control credits this year. We have just 2 months to close a gap of over 80 credits. Columbus CCOP members are asked to continue their focus of screening new patients to determine if they are eligible for cancer control studies. Below is a list of cancer control trials currently available through the Columbus CCOP. As always ... thank you for your support!

| | |
|-------------|---|
| ECOG E5597 | Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage 1 Non-Small Cell Lung Cancer |
| HLMCC 0501 | Stress Management Therapy for Patients Undergoing Chemotherapy. Open for Hispanic patients only. |
| NCCTG N04CA | Pilocarpine for Vaginal Dryness: A Phase III Randomized, Double Blind, Placebo-Controlled Study |
| NCCTG N07C2 | The Use of Wisconsin Ginseng (panax quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study |
| NCCTG N08C1 | Palitaxel-Associated Acute Pain Syndrome Natural History Study |
| SWOG S0424 | Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men |
| SWOG S0702 | A prospective observational multicenter cohort study to assess the incidence of osteonecrosis of the jaw in patients with bone metastases starting zoledronic acid. |
| URCC 07079 | Prevention of Pegfilgrastim-Induced Bone Pain (PIBP): A Phase III Double-Blind, Placebo-Controlled Clinical Trial |
| URCC U1105 | Prevention of Delayed Nausea - A Phase III Double-Blind Placebo-Controlled Clinical Trial |
| URCC U1701 | Dyspnea in Cancer Patients |



MARCH IS NATIONAL COLORECTAL CANCER AWARENESS MONTH



COLORECTAL SCREENING SAVES LIVES!

OUR MISSION: The Columbus Community Clinical Oncology Program (Columbus CCOP) strives to deliver state-of-the-art cancer care to patients in their communities through clinical trials. This allows individuals to remain in their own neighborhoods while receiving the latest and best in cancer screenings, diagnostic care and treatment plans.

Please send newsletter comments to steveo@columbusccop.org



MARK YOUR CALENDAR

- **April 1, 2009: CCOP Nurses Meeting.** The start time is 12:30 pm. A presentation titled “Ixempra in the Treatment of Metastatic Breast Cancer” will be given by Christine Quirk, PhD, Bristol-Myers Squibb.
- **April 2, 2009: Update on Melanoma. This program is full.** Dr. John Kirkwood will return to present the latest updates on Melanoma at the Polaris Brio Tuscan Grille.
- **June 18, 2009:** Mark your calendar for the **2009 ASCO Review.** The annual Columbus CCOP 2009 ASCO Review will once again feature nationally recognized speakers who will summarize the highlights of the annual ASCO Meeting. This has been a highly regarded regional CME event since 2000 and you will not want to miss it! Registration will be available in April.



**2009
ASCO
REVIEW
JUNE 18, 2009**

NCI TRIAL NEWS

The following trials are now open for accrual:

NCCTG N0821: A phase II first-line study of a combination of pemetrexed, carboplatin and bevacizumab in advanced nonsquamous non-small cell lung cancer evaluating efficacy and tolerability in elderly patients (age \geq 70 yrs) with good performance status

SWOG S0703: A phase II trial of azacitidine (NSC-102816) plus gemtuzumab ozogamicin as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 acute myeloid leukemia

SWOG S0720: A phase II ERCC1 and RRM1-based adjuvant therapy trial in patients with stage 1 non-small cell lung cancer

SWOG S0722: A phase II trial of MTOR inhibitor, everolimus (RAD001), in malignant pleural mesothelioma (MPM)

NCCTG N08C1: Palitaxel-Associated Acute Pain Syndrome Natural History Study


[Please remember to consider cancer control protocols found in the Columbus CCOP protocol book or at \[www.columbusccop.org\]\(http://www.columbusccop.org\).](#)

INDUSTRY TRIAL NEWS


The following industry trial is open for accrual:

- **NSABP B-41:** This is a randomized phase III trial of neoadjuvant therapy for patients with palpable and operable HER2-positive breast cancer comparing the combination of trastuzumab plus lapatinib to trastuzumab and to lapatinib administered with weekly paclitaxel following AC accompanied by correlative science studies to identify predictors of pathologic complete response.

Protocol and consent forms can be found at www.columbusccop.org



As many of you know, especially those who have been reading my notes in past newsletters, accrual has been more of an issue this past year than in previous years. We still have a way to go to equal last years experience, but I need to thank all of you who made last month the highest accrual month for the year. We did well in cancer control accrual as well as treatment studies. There are more studies available and we will continue our efforts to have treatment trials available for as many diseases and stages as possible. As we all agree, research cures cancer.



Among the newer trials available is a cancer control study approved Thursday, March 19th, by the IRB. The people at Mayo Clinic and elsewhere have reported on a possible acute pain syndrome after taxol therapy. We now have a simple study to assess the incidence of this toxicity in patients with any cancer starting on taxol or a taxol-containing regimen, whether it be weekly or tri-weekly therapy. Patients will be asked to fill out a page of short questions, for a few days after therapy, to determine if they have pain, numbness, etc. That's basically it. It should be easy to accrue a number of patients to this trial. Sorry, taxotere therapy is not included.

One of my goals over the next few months is to visit some of our member institutions to meet with people directly and to see how we are doing and what we could be doing better. Hope to see you at these visits. Of course, you should always feel free to e-mail me or just pick up the phone and call. There are a number of ways to contact me.

Phil Kuebler

WAYS TO GIVE! COLUMBUS CCOP DONATIONS

The Columbus Community Clinical Oncology Program is a community based non-profit organization with a mission to deliver state-of-the-art cancer care to patients in their communities through clinical trials.



We accept, and are extremely grateful for, private donations from individuals. The Columbus CCOP is a 501 (c)(3) organization, and your contribution is tax deductible.

You can help support the Columbus CCOP in the following ways:

You can fill out a donation form and mail your check to the address shown at the bottom of the form. Go to <http://www.columbusccop.org/news/nletters/CCOP%20Donation%20Form.pdf>

You can also make a credit card donation through the Columbus Foundation at www.columbusfoundation.org. Users should register for a username and password prior to logging in. On the Columbus Foundation Home Page select PowerPhilanthropy Login. Click on Create a Username and Password. Click on Sign-up form under Public Users. Complete the form and click on Submit. Your user ID and password will be sent to your email. To donate to the Columbus CCOP select PowerPhilanthropy Login at the top of the page. Enter the user name and password that was emailed to you. Select View Non-profit Portraits, then enter Columbus Community Clinical Oncology Program and click on Search. Click on the Give Now button on the right side of the screen.

DID YOU KNOW?

New on the NCI website: Revised and reviewed titles for NCI fact sheets, from <http://www.cancer.gov/cancertopics/factsheet/>.

Also new on the NCI website: Financial Assistance and Other Resources for People with Cancer (FS 8.3, 2/5/09), at <http://www.cancer.gov/cancertopics/factsheet/Support/financial-resources>

The 1999-2005 United States Cancer Statistics (USCS): Incidence and Mortality report is now available. This Web-based resource includes the official federal statistics on cancer incidence from registries that have high-quality data and cancer mortality statistics for each year and 2001-2005 combined. It is produced by the CDC and NCI, in collaboration with the North American Association of Central Cancer Registries (NAACCR). Some of the features available are graphs of the top ten cancers, state-vs.-national comparisons, and cancers ranked by state. Tables of specific cancer types, selected groupings (state and regional), and race and ethnicity information are included. To explore the data sets and tables, go to <http://apps.nccd.cdc.gov/uscs>.



MARCH IS NATIONAL COLORECTAL CANCER MONTH

According to the Center for Disease Control, colorectal cancer, among cancers that affect both men and women, is the second leading cause of cancer-related deaths in the United States. Colorectal cancer also is one of the most commonly diagnosed cancers in the United States.

The risk of developing colorectal cancer increases with advancing age. More than 90% of cases occur in people older than 50. It is estimated that as many as 60% of colorectal cancer deaths could be prevented if all men and women aged 50 years or older were screened. It is recommended that screening for colorectal cancer start soon after turning 50, then continue getting screened at regular intervals.

To learn more, please visit:

<http://www.cdc.gov/Features/ColorectalAwareness/>

<http://www.cancer.org/docroot/home/index.asp>

<http://www.cancer.gov/cancertopics/types/colon-and-rectal>

